Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change (functional) | = -38 % | Percent change in immune R16 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = -36 % | Percent change in nonimmune L16 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = -33 % | Compound was tested by carrageenan -induced paw edema for percent change in paw volume of control sham operated rats at 50 mg/kg. | ChEMBL. | 4032421 |
Change (functional) | = -25 % | Percent change in nonimmune L3 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = 73 % | Immunoregulatory activity against mouse contact sensitivity was evaluated as percent change | ChEMBL. | 4032421 |
Change (functional) | = 73 % | Immunoregulatory activity against mouse contact sensitivity was evaluated as percent change | ChEMBL. | 4032421 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.